Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
Seenu M. Hariprasad, Richard Gale, Christina Y. Weng, et al.
Ophthalmology and Therapy (2022) Vol. 11, Iss. 3, pp. 959-982
Open Access | Times Cited: 22

Showing 22 citing articles:

Ocular Delivery of Therapeutic Agents by Cell-Penetrating Peptides
Nguyễn Thị Thanh Nhàn, Daniel E. Maidana, Kaori Yamada
Cells (2023) Vol. 12, Iss. 7, pp. 1071-1071
Open Access | Times Cited: 20
Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration
Tomiko Sunaga, M Maeda, Rosella Saulle, et al.
Cochrane library (2024) Vol. 2024, Iss. 7
Closed Access | Times Cited: 5
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
Amin Hatamnejad, Rohan Dadak, Samantha Orr, et al.
BMJ Open Ophthalmology (2023) Vol. 8, Iss. 1, pp. e001205-e001205
Open Access | Times Cited: 11
Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review
Neil M. Bressler, Peter K. Kaiser, V. Diana, et al.
Survey of Ophthalmology (2024) Vol. 69, Iss. 4, pp. 521-538
Open Access | Times Cited: 4
Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review
Seenu M. Hariprasad, Frank G. Holz, Carl V. Asche, et al.
Ophthalmology and Therapy (2025)
Open Access
Patient’s and Consultant’s Views and Perceptions on Switching from an Originator Biologic to Biosimilar Medication: A Qualitative Study
Denise Rosembert, Michael Twigg, David Wright
Pharmacy (2024) Vol. 12, Iss. 2, pp. 65-65
Open Access | Times Cited: 3
Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Anat Loewenstein, Norbert Czumbel, Jan Ernest, et al.
Ophthalmology Retina (2023) Vol. 7, Iss. 9, pp. 753-761
Open Access | Times Cited: 8
Approved treatments for neovascular age-related macular degeneration: current safety and future directions
Hannah Khan, Aamir Aziz, Zoha A. Khanani, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 9, pp. 1109-1114
Closed Access | Times Cited: 2
Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial
Srinivas R. Sadda, Mario Bradvica, Attila Vajas, et al.
BMJ Open Ophthalmology (2023) Vol. 8, Iss. 1, pp. e001561-e001561
Open Access | Times Cited: 4
Safety of recent ophthalmic drugs and devices for wet macular degeneration
Elise Timtim, Christina Y. Weng, Avni P. Finn
Current Opinion in Ophthalmology (2023) Vol. 34, Iss. 5, pp. 363-368
Closed Access | Times Cited: 2
Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders
Matthew Driban, Nikita Kedia, Supriya Arora, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1125-1139
Closed Access | Times Cited: 2
Biosimilars in the Retina
Daniel Barmas-Alamdari, Barbara Cortes, Ravneet Rai, et al.
Advances in Ophthalmology and Optometry (2024) Vol. 9, Iss. 1, pp. 175-185
Closed Access
Treatment Regimens of Neovascular Form of Age-Related Macular Degeneration. A Review
Zlatica Fellner, Nora Majtánová, Petr Kolář, et al.
Czech and Slovak Ophthalmology (2024) Vol. 80, Iss. 6, pp. 287-293
Closed Access
One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients
Mami Tomita, Manabu Yamamoto, Kumiko Hirayama, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4641-4641
Open Access
Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial
Jan Hamouz, Agnieszka Nowosielska, Anna Święch-Zubilewicz, et al.
Ophthalmology Retina (2024)
Closed Access
Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1
Cheryl L. Rowe-Rendleman
Journal of Ocular Pharmacology and Therapeutics (2024) Vol. 40, Iss. 9, pp. 550-552
Closed Access
Retinal Vein Occlusion Guidelines
Jan Studnička, Jan Němčanský, Daniela Vysloužilová, et al.
Czech and Slovak Ophthalmology (2024) Vol. 80, Iss. 6, pp. 296-303
Closed Access
Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration

Klinische Monatsblätter für Augenheilkunde (2023) Vol. 240, Iss. 02, pp. 180-189
Closed Access | Times Cited: 1
Ergänzende Stellungnahme zu den IVOM-Medikamenten zur Therapie des diabetischen Makulaödems mit fovealer Beteiligung

Klinische Monatsblätter für Augenheilkunde (2023) Vol. 240, Iss. 03, pp. 327-331
Closed Access
Biosimilars in the Treatment of Retinal Disease in the United States
Priya S. Vakharia, David Eichenbaum, Caroline R. Baumal
Ophthalmic surgery, lasers & imaging retina (2023) Vol. 54, Iss. 6, pp. 362-366
Closed Access
Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration
Daniel Pauleikhoff, Bernd Bertram, Nicolas Feltgen, et al.
Deleted Journal (2022) Vol. 120, Iss. 2, pp. 169-177
Closed Access
Ergänzende Stellungnahme zu den IVOM-Medikamenten zur Therapie des diabetischen Makulaödems mit fovealer Beteiligung
Bernd Bertram, Nicolas Feltgen, Horst Helbig, et al.
Deleted Journal (2022) Vol. 120, Iss. 3, pp. 273-275
Closed Access
Page 1

Scroll to top